Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci

Sexually Transmitted Infections

Volumn 85, Issue 4, 2009, Pages 256-258

  Tapsall, J W ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CEFIXIME; CEFODIZIME; CEFTIBUTEN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; GENERIC DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CONTAMINATION; DRUG TREATMENT FAILURE; GONORRHEA; HUMAN; INFECTION CONTROL; MEDICAL PRACTICE; NEISSERIA GONORRHOEAE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; WORLD HEALTH ORGANIZATION;

ANTI-BACTERIAL AGENTS; ASIA, SOUTHEASTERN; AUSTRALIA; CEFIXIME; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GONORRHEA; HUMANS; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; PACIFIC ISLANDS; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

EID: 68249126403     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sti.2008.035337     Document Type: Article

References (10)

1. Yokoi S, Takashi Deguchi T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007;13:1275-1277
2. Lo JYC, Ho KM, Leung AOC, et al. Ceftibuten resistance and treatment failure in Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008;52:3564-3567
3. Wong W-W, Huang C-T, Li L-H, et al. Molecular epidemiological identification of Neisseria gonorrhoeae clonal clusters with distinct susceptibility profiles associated with specific groups at high risk of contracting human immunodeficiency virus and syphilis. J Clin Microbiol 2008;46:3931-3934
4. Tapsall JW, Ray S, Whiley D, et al. Distribution of a cephalosporin resistant sequence type of Neisseria gonorrhoeae with a mosaic PBP-2 associated with treatment failure in the Asia-Pacific region [Abstract PO52]. Proceedings of the 16th International Pathogenic Neisseria Conference. 7-12 September 2008, Rotterdam. http://neisseria.org/ipnc/ (accessed April 2009).
5. Nicholas RA, Zhao S, Tomberg J, et al. Genetics of intermediate resistance to expanded-spectrum cephalosporins in Neisseria gonorrhoeae [Abstract PO54]. Proceedings of the 16th International Pathogenic Neisseria Conference. 7-12 September 2008, Rotterdam. http://neisseria.org/ipnc/ (accessed April 2009).
6. Lindberg R, Fredlund H, Nicholas R, et al. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007;51:2117-2122 (Pubitemid 46903103)
7. Tapsall J. Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment for gonorrhea: some possible remedies. Expert Rev Anti Infect Ther 2006;4:619-625 (Pubitemid 44523940)
8. Workowski KA, Berman SM, Douglas Jr JM. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008;148:606-613
9. Deguchi T, Yasuda M. Lack of nationwide surveillance of antimicrobial resistance in Neisseria gonorrhoeae in Japan. Ann Intern Med 2008;149:363-364
10. Muratani T, Inatomi H, Ando Y, et al. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol 2008;15:837-842